Article in International journal of molecular sciences, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 36% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
3 citing papers in PubMed, 2 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
7 authors at 5 institutions in 3 countries.
Dimitrios VlachakisGenetics Laboratory, Department of Biotechnology, Agricultural University of Athens, 75 Iera Odos Street, 11855 Athens, Greece. dimvl@aua.gr.ORCID 0000-0003-1823-6102
Nikolaos E LabrouLaboratory of Enzyme Technology, Department of Biotechnology, School of Food, Biotechnology and Development, Agricultural University of Athens, 75 Iera Odos Street, 11855 Athens, Greece. lambrou@aua.gr.ORCID 0000-0003-1925-9867
Costas IliopoulosDepartment of Informatics, Faculty of Natural and Mathematical Sciences, King's College London, Strand, London WC2R 2LS, UK. csi@kcl.ac.uk.
John HardyDepartment of Neurodegenerative disease, UCL Institute of Neurology, Queen Square, London WC1N 3BG, UK. j.hardy@ucl.ac.uk.
Patrick A LewisDepartment of Neurodegenerative disease, UCL Institute of Neurology, Queen Square, London WC1N 3BG, UK. p.a.lewis@reading.ac.uk.
Hardy RideoutDivision of Basic Neurosciences; Biomedical Research Foundation of the Academy of Athens, Soranou Efessiou 4, 11527 Athens, Greece. hrideout@bioacademy.gr.
Daniah TrabzuniDepartment of Neurodegenerative disease, UCL Institute of Neurology, Queen Square, London WC1N 3BG, UK. d.trabzuni@ucl.ac.uk.
Agricultural University of Athens · GRNational Hospital for Neurology and Neurosurgery · GBAcademy of Athens · GRKing Faisal Specialist Hospital & Research Centre · SAKing's College London · GB
Funding
Medical Research Council MR/G0901254Medical Research Council MR/L010933/1Medical Research Council MR/N026004/1Michael J. Fox Foundation for Parkinson's Research 524995Michael J. Fox Foundation for Parkinson's Research 7722.01Michael J. Fox Foundation for Parkinson's Research 8418.01Parkinson's UK F-1002
6 · The paper itself
Abstract
Leucine-rich repeat kinase 2 (LRRK2) is a large protein of unclear function. Rare mutations in the
Indexed as
RNA SplicingGene ExpressionHumansLeucine-Rich Repeat Serine-Threonine Protein Kinase-2Models, MolecularParkinson DiseaseProtein ConformationProtein DomainsProtein Interaction Domains and MotifsRNA, MessengerStructure-Activity RelationshipSubstantia NigraLeucine-Rich Repeat Serine-Threonine Protein Kinase-2RNA, MessengerHuman brain substantia nigraLRRK2 mRNA expressionParkinson’s disease (PD)ROC/COR domain splicing eventsWD40 domain in protein structure
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Insights into the Influence of Specific Splicing Events on the Structural Organization of · full record | OpenQuestion